Combinostics
Using a combination of science and AI technology, we aim to improve the lives of patients with neurological disorders.
Using a combination of science and AI technology, we aim to improve the lives of patients with neurological disorders.
Combinostics is a Finland-based startup that utilizes a combination of science and AI technology with the purpose of enhancing the lives of patients suffering from neurological disorders. The company's cNeuro™ platform integrates innovative AI technology with a comprehensive view of patient data, including imaging biomarkers, demographic and clinical data, neuropsychology test results, and other biomarkers. This approach empowers clinicians to make reliable, evidence-based diagnostic and management decisions for patients with neurological disorders. Combinostics was founded in 2014 and operates within the industries of Enterprise Software, Health Care, Information Technology, and Robotics. The company most recently received a €3.90M Series A investment on 21 November 2019. The investors behind this funding round were Industrifonden and NordicNinja VC.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €3.90M | 2 |
|
21 Nov 2019 |
| Non Equity Assistance | Unknown | 1 |
|
17 Dec 2018 |
| Seed Round | Unknown | 1 | LEO Innovation Lab | 10 Mar 2017 |
| Seed Round | Unknown | 1 | LEO Innovation Lab | 17 May 2016 |
| Seed Round | €350.00K | - | 15 Dec 2014 |
No recent news or press coverage available for Combinostics.
We care about your data, and we'd love to use cookies make your experience better.
